CAJ | 학술논문

目的：观察卡培他滨单药对晚期复发性卵巢癌患者的疗效和不良反应。方法27例晚期复发性卵巢癌患者,给予卡培他滨2500 mg/m2,2次/d,连用14 d,休息7 d,每21天重复,直到疾病进展,最多6周期。结果部分缓解11例,稳定10例,疾病进展6例,总有效率40.7%,肿瘤控制率77.8%,中位肿瘤进展时间(mTTP)7.8个月。不良反应有：Ⅰ~Ⅱ度手足综合征5例,发生率18.5%,Ⅰ~Ⅱ度骨髓抑制6例,发生率22.2%,Ⅰ度腹泻2例,发生率为7.4%,Ⅰ度消化道反应2例,发生率为7.4%。结论卡培他滨单药治疗晚期复发性卵巢癌患者有较高疾病控制率,不良反应轻微,值得临床推广。
목적：관찰잡배타빈단약대만기복발성란소암환자적료효화불량반응。방법27례만기복발성란소암환자,급여잡배타빈2500 mg/m2,2차/d,련용14 d,휴식7 d,매21천중복,직도질병진전,최다6주기。결과부분완해11례,은정10례,질병진전6례,총유효솔40.7%,종류공제솔77.8%,중위종류진전시간(mTTP)7.8개월。불량반응유：Ⅰ~Ⅱ도수족종합정5례,발생솔18.5%,Ⅰ~Ⅱ도골수억제6례,발생솔22.2%,Ⅰ도복사2례,발생솔위7.4%,Ⅰ도소화도반응2례,발생솔위7.4%。결론잡배타빈단약치료만기복발성란소암환자유교고질병공제솔,불량반응경미,치득림상추엄。
Objective To observe the curative effect and adverse reactions of capecitabine in monotherapy of advanced recurrent ovarian cancer. Methods A total of 27 patients with advanced recurrent ovarian cancer received capecitabine as 2500 mg/m2 by 2 times/d for 14 d, followed by 7 d of rest. The treatment repeated every 21 d until progression of disease, for 6 courses at most. Results There were 11 cases with partial remission, 10 cases with stable disease and 6 cases with progressive disease. The total effective rate was 40.7%, tumor control rate was 77.8%, and median time to tumor progression (mTTP) was 7.8 months. Adverse reactions included 5 cases withⅠ~Ⅱdegree of hand-foot syndrome, with occurrence rate as 18.5%, 6 cases withⅠ~Ⅱdegree of myelosuppression, with occurrence rate as 22.2%, 2 cases withⅠdegree of diarrhea, with occurrence rate as 7.4%, and 2 cases withⅠdegree of gastrointestinal reaction, with occurrence rate as 7.4%. Conclusion Implement of capecitabine in monotherapy of advanced recurrent ovarian cancer can provide high control group with mild adverse reactions, and it is worthy of clinical promotion.